APUS
APIMEDS PHARMA (APUS)
NYSE
$2.93+$0.04 (+1.38%)
Price as of Oct 23, 2026 7:49 PM EDT
  • $4.4M
    Market Cap
  • -85.40%
    1-Year Change
  • Drug Manufacturers - Specialty & Generic
    Industry

Key Performance

More
  • Earnings Score: N/A
  • Momentum Score: 81
  • True Yield: N/A
  • Financial Health Score: N/A
TradeSmith Loading

Latest Research & News

MindWave Innovations Signs 3 Client Network Agreements in 10 Days, Extending MindChain into Climate Finance, Sports Media and Insurance; Apimeds Pharmaceuticals US Provides Required NYSE American Disclosure

MindWave Innovations Inc. USA, a subsidiary of Apimeds Pharmaceuticals US, Inc., signed three blockchain network agreements within 10 days with AQUAE Holdings (climate finance), Flash Sports & Media Holdings (sports media), and BlockAssure Inc. (insurance). Each agreement follows the same model where MindWave builds and operates dedicated MindChain networks while receiving 20% token/credit allocations. However, the parent company disclosed substantial doubt about its ability to continue as a going concern.

10/09/2026, 6:00 PM • GlobeNewswire

IBN Initiates Coverage of Apimeds Pharmaceuticals US, Inc.

Apimeds Pharmaceuticals US (NYSE American: APUS), a clinical-stage biopharmaceutical company developing non-opioid therapies for pain management, has engaged IBN to enhance its corporate communications strategy. The company's subsidiary, MindWave Innovations, is developing blockchain-based institutional digital asset infrastructure combining custody, reporting, and portfolio management for Bitcoin reserves and digital asset participation.

09/18/2026, 2:00 PM • GlobeNewswire

APUS Investors Have Opportunity to Join Apimeds Pharmaceuticals US, Inc. Fraud Investigation with the Schall Law Firm

The Schall Law Firm is investigating Apimeds Pharmaceuticals US, Inc. (APUS), Elite Express Holding Inc. (ETS), and Decent Holding Inc. (DXST) for potential securities law violations, including allegations of false statements and failure to disclose material information to investors. Affected shareholders are encouraged to participate in the investigation.

04/26/2026, 8:12 PM • GlobeNewswire

Peers

Statistics

More
Day Range
$2.81
$3.18
$2.89
1-Year Range
$0.64
$8.00
$2.89
Latest Close$2.89
Change
-$0.27 (-9.34%)
Volume35,725
Market Cap$4.4M
Shares Outstanding1.5M
P/E (TTM)-0.02
Diluted EPS (TTM)-$117.84
Enterprise Value$25.8M

Information as of 10/23/2026

Company Profile

APIMEDS PHARMACEUTICALS US INC
APIMEDS PHARMACEUTICALS US INC
https://www.mindwavedao.com
$4.4M
Market Cap
-$58.2M
Net Income
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
100 Matawan Rd, Matawan, NJ, United States, 07747
848 201 5010

Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company was incorporated in 2020 and is based in Matawan, New Jersey. Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Inscobee., Inc.

Key Executives

  • Erik C. Emerson
  • Erick J. Frim
  • Eric Michael Sherb
  • Captain Sandeep Yadav
  • Amardeep Singh

Current Ownership Distribution

  • Institutions970,967 (62.45%)
  • Mutual Funds315,813 (20.31%)
  • Insiders268,000 (17.24%)
  • Other0 (0.00%)